Surrozen, Inc/de 8-K filings

Surrozen, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Surrozen announced its first quarter 2026 financial results, reporting $5 million in collaboration revenue and maintaining a strong cash position of $106.9 million, while advancing its SZN-8141 IND submission.

Surrozen, Inc. announced its full-year 2025 financial results, highlighted by pipeline advancements, a $5 million milestone payment from Boehringer Ingelheim, and a significant increase in net loss.

Dr. Shao-Lee Lin has resigned from Surrozen, Inc.'s Board of Directors, effective January 26, 2026, with no reported disagreements.

Surrozen, Inc. announced Andrew Maleki as its new CFO and reported a significant net loss of $71.6 million for Q3 2025, alongside progress in its ophthalmology pipeline.

Surrozen, Inc. announced the termination of its collaboration agreement with TCGFB, Inc., effective November 13, 2025, without penalties.

Surrozen, Inc. has entered into a sales agreement with TD Cowen to offer and sell up to $50 million of its common stock through an at-the-market offering.

Surrozen, Inc. announced a significant net income of $39.7 million for Q2 2025, driven by non-cash gains, alongside key advancements in its ophthalmology pipeline and leadership appointments.

Surrozen, Inc. held its 2025 Annual Meeting of Stockholders on May 14, 2025, and announced the results, including the election of directors and ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm.

Surrozen announced its Q1 2025 financial results, highlighting a strategic shift to ophthalmology and discontinuing its SZN-043 program.

Surrozen, Inc. reported its financial results for the fourth quarter and full year 2024, highlighting progress in its ophthalmology pipeline and a recent financing.

Surrozen, Inc. has successfully completed the first tranche of a private placement, raising $76.4 million, with a second tranche of $98.6 million contingent on FDA clearance for its SZN-8141 program.

Surrozen secures $175 million in private placement to advance its ophthalmology pipeline, discontinuing its SZN-043 program for severe alcohol-associated hepatitis.

Surrozen reports encouraging Phase 1b trial results for SZN-043, a $10 million milestone payment from Boehringer Ingelheim, and a new research collaboration with TCGFB.

Surrozen, Inc. has extended its headquarters lease in South San Francisco by 48 months, with an option to terminate early under certain conditions.

Surrozen reported its second quarter 2024 financial results, highlighted by progress in clinical trials for SZN-043 and advancements in their SWEETS technology platform.

Surrozen, Inc. reports the resignation of board member Tim Kutzkey, effective June 30, 2024.

Surrozen, Inc. held its 2024 Annual Meeting of Stockholders on June 5, 2024, where directors were elected and the appointment of Ernst & Young LLP as the company's independent auditor was ratified.

Surrozen reported its first quarter 2024 financial results, highlighting progress in clinical trials and research programs, and a recent financing that boosted its cash position.

Surrozen, Inc. has entered into a securities purchase agreement for a private placement, raising approximately $17.5 million to fund clinical trials and working capital.

Surrozen's SZN-043 demonstrated acceptable safety and promising pharmacodynamic effects in a Phase 1a trial, leading to the initiation of a Phase 1b trial for severe alcohol-associated hepatitis.

Surrozen, Inc. has appointed its current Chief Financial Officer, Charles Williams, to the additional role of Chief Operating Officer, effective February 1, 2024.

Surrozen completes enrollment for SZN-043 Phase 1a trial, anticipates data release in Q1 2024, and discontinues development of SZN-1326 for IBD due to safety and strategic concerns.